Cartesian Therapeutics appoints Adrian Bot to board; brings CAR T and RNA therapy expertise

Cartesian Therapeutics, Inc.

Appointed Adrian Bot, M.D., Ph.D., as Class II director effective Dec 16, 2025; will serve on Science and Technology Committee.
Bot brings three decades of R&D experience in CAR T, cell/gene therapy and nanomedicines; former CSO of Capstan Therapeutics.
Initial compensation includes option for 17,200 shares at $8.29 and RSUs for 5,800 shares, with multi-year vesting schedules.
CEO highlights Bot's role in first-in-class CAR T therapies and Capstan's acquisition by Abbvie, relevant to Cartesian's autoimmunity focus.
Company is a clinical-stage biotech advancing cell therapy for autoimmune diseases; expects a critical year of execution.

item 5.02 item 5.05 item 7.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Cartesian Therapeutics, Inc.: Adopted an updated version of the Code of Business Conduct and Ethics, effective December 16, 2025, superseding prior code (effective 2025-12-16).

Change: code of ethics
Effective: 2025-12-16

Exact text from the filing

On December 16, 2025, the Board adopted an updated version of the Cartesian Therapeutics, Inc. Code of Business Conduct and Ethics (the “Code”), effective as of such date.

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Cartesian Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001453687-25-000140

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.